Disease Management & Health Outcomes

, Volume 15, Issue 3, pp 165–179 | Cite as

Treating Allergic Asthma with Omalizumab

Review Article

Abstract

Asthma is a chronic condition with characteristics that make it an ideal target for interventions used within disease state management in managed care settings. It affects a substantial population of patients and imposes an increasingly significant global societal burden. Despite the availability of many asthma medications and easily accessed publications providing step-wise guidance for asthma management, there are still patients whose condition is not well controlled. Hence, there is a continuing need for unique treatment options. Omalizumab is a subcutaneously administered monoclonal anti-IgE antibody that reduces free IgE concentrations and promotes down-regulation of IgE receptors on basophils. This relatively new pharmacologic intervention has been shown to reduce inhaled corticosteroid (ICS) and rescue medication requirements, and improve asthma control and quality of life in patients with moderate to severe allergic asthma with disease poorly controlled by ICSs. However, because of its high cost relative to other asthma drug therapies, health plans/payers must ensure that criteria for its use are clearly identified so as to target patients who will most likely benefit from such therapy. Omalizumab may need to be restricted to asthma patients with severe persistent allergy who are categorized as ‘high risk’ (e.g. patients with a recent history of frequent intubations, emergency room visits, overnight hospitalizations, or intensive care unit admissions for asthma exacerbations) who remain symptomatic despite appropriate maximal maintenance therapy for the severity of their disease. If restricted to this narrowly defined population of patients with allergic asthma, cost-of-care studies suggest that the high cost of this product could be offset by savings resulting from the less frequent use of high-intensity medical services for asthma exacerbations.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Academy of Managed Care Pharmacy. Concepts in managed care pharmacy, disease state management/health management [online]. Available from URL: http://www.amcp.org/data/nav_content/Disease%20State%20ManagementHealth%20Management.pdf [Accessed 2007 Mar 28]
  2. 2.
    Lemanske RF, Busse WW. Asthma. J Allergy Clin Immunol 2003; 111 (2 Suppl.): S502–19PubMedCrossRefGoogle Scholar
  3. 3.
    American Lung Association. Asthma & children. Asthma in children fact sheet [online]. Available from URL: http://www.lungusa.org/site/pp.asp?.c=dvLUK9O0E&b=44352 [Accessed 2007 Mar 28]
  4. 4.
    American Lung Association. Asthma & adults. Asthma in adults fact sheet [online]. Available from URL: http://www.lungusa.org/site/pp.asp?.c=dvLUK9O0E&b=22596 [Accessed 2007 Mar 28]
  5. 5.
    Bousquet J, Bousquet PJ, Godard P, et al. The public health implications of asthma. Bull World Health Organ 2005; 83: 548–54PubMedGoogle Scholar
  6. 6.
    Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2006 [online]. Available from URL: http://www.ginasthma.com [Accessed 2007 Mar 19]
  7. 7.
    Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics 2002. Bethesda (MD): National Institutes of Health, National Heart Lung and Blood Institute, 2003 Jun. NIH publication no.: 02-5074Google Scholar
  8. 8.
    Disease Management Association of America. DMAA definition of disease management [online]. Available from URL: http://www.dmaa.org/dm_definition.asp [Accessed 2007 Mar 28]
  9. 9.
    British Thoracic Society Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma. Revised edition November 2005 [online]. Available from URL: http://www.enterpriseportal2.co.uk/filestore/bts/asthmaupdatenov05.pdf [Accessed 2007 Mar 28]
  10. 10.
    Garcia G, Adler M, Humbert M. Difficult asthma. Allergy 2003; 58: 114–21PubMedCrossRefGoogle Scholar
  11. 11.
    Storms WW. Unmet needs in the treatment of allergic asthma: potential role of novel biologic therapies. J Manag Care Pharm 2003; 9(6): 534–43PubMedGoogle Scholar
  12. 12.
    Rosenwasser LJ, Nash DB. Incorporating omalizumab into asthma treatment guidelines: consensus panel recommendations. P&T 2003; 28: 400–10Google Scholar
  13. 13.
    Miller TP, Reeves MJ. Lack of cost-effectiveness of omalizumab. J Allergy Clin Immunol 2005; 115: 429–30PubMedCrossRefGoogle Scholar
  14. 14.
    Rambasek TE, Lang DM, Kavuru MS, et al. Omalizumab: where does it fit into current asthma management? Cleve Clin J Med 2004; 71: 251–61PubMedCrossRefGoogle Scholar
  15. 15.
    Belliveau PP, Lahoz MR. Evaluation of omalizumab from a health plan perspective. J Manag Care Pharm 2005; 11: 735–45PubMedGoogle Scholar
  16. 16.
    Curtiss FR. Selectivity and specificity are the keys to cost-effective use of omalizumab for allergic asthma. J Manag Care Pharm 2005; 11: 774–5PubMedGoogle Scholar
  17. 17.
    Gunter MJ. The role of the ECHO model in outcomes research and clinical practice improvement. Am J Manag Care 1999 (2 Suppl.); 5: S217–24PubMedGoogle Scholar
  18. 18.
    Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354: 2689–95PubMedCrossRefGoogle Scholar
  19. 19.
    Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. MedGenMed 2005; 7(1): 27 [online]. Available at URL: http://www.medscape.com/viewarticle/494543 [Accessed 2007 Mar 28]PubMedGoogle Scholar
  20. 20.
    Goldsby RA, Kindt TJ, Osborne BA, et al., editors. Immunology. 5th ed. New York (NY): W.H. Freeman and Company, 2003Google Scholar
  21. 21.
    Hook WA, Zinsser FU, Berenstein EH, et al. Monoclonal antibodies defining epitopes on human IgE. Mol Immunol 1991; 28: 631–9PubMedCrossRefGoogle Scholar
  22. 22.
    Presta L, Shields R, O’Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269: 26368–73PubMedGoogle Scholar
  23. 23.
    Oettgen HC, Geha RS. IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999; 104: 829–35PubMedCrossRefGoogle Scholar
  24. 24.
    Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001; 108: S65–71PubMedCrossRefGoogle Scholar
  25. 25.
    Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax 1999; 54: 268–72PubMedCrossRefGoogle Scholar
  26. 26.
    Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 271–7PubMedCrossRefGoogle Scholar
  27. 27.
    Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health, National Heart Lung and Blood Institute, 1997 Jul. NIH Publication: 97-4051Google Scholar
  28. 28.
    Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34: 10474–82PubMedCrossRefGoogle Scholar
  29. 29.
    Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18: 157–62PubMedCrossRefGoogle Scholar
  30. 30.
    Malveaux FJ, Conroy MC, Adkinson NF, et al. IgE receptors on human basophils: relationship to serum IgE concentration. J Clin Invest 1978; 62: 176–81PubMedCrossRefGoogle Scholar
  31. 31.
    MacGlashan D, McKenzie-White J, Chichester K, et al. In vitro regulation of FcεRIα expression on human basophils by IgE antibody. Blood 1998; 91: 1633–43PubMedGoogle Scholar
  32. 32.
    MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438–45PubMedGoogle Scholar
  33. 33.
    Milgrom H, Fick RB, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999; 341: 1966–73PubMedCrossRefGoogle Scholar
  34. 34.
    Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254–61PubMedCrossRefGoogle Scholar
  35. 35.
    Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe asthma. J Allergy Clin Immunol 2001; 108: 184–90PubMedCrossRefGoogle Scholar
  36. 36.
    Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107: 308–12PubMedCrossRefGoogle Scholar
  37. 37.
    Saban R, Haak-Frendscho M, Zine M, et al. Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 1994; 94: 836–43PubMedCrossRefGoogle Scholar
  38. 38.
    Jones C, Endicott L, Kaufman MB. From asthma severity to asthma control: identification of new guidelines. J Manag Care Pharm 2006; 12 (9 Suppl.): 1–20Google Scholar
  39. 39.
    Masoli M, Fabian D, Holt S, et al. The global burden of asthma: summary of the GINA Dissemination Committee Report. Allergy 2004; 59: 469–78PubMedCrossRefGoogle Scholar
  40. 40.
    Australian Centre for Asthma Monitoring. Asthma in Australia 2005. Canberra (ACT): Australian Institute of Health and Welfare, 2005 [online]. Availble from URL: http://www.aihw.gov.au/publications/acm/aia05/aia05.pdf [Accessed 2007 Mar 28]Google Scholar
  41. 41.
    The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225–32CrossRefGoogle Scholar
  42. 42.
    Asher M, Montefort S, Bjorksten B et al. and the ISAAC Phase Three Study Group. Worldwide time trends in prevalence of asthma, allergic rhinoconjunctivitis, and atopic eczema in childhood: ISAAC phases one and three repeat multicoun-try cross-sectional surveys. Lancet 2006; 368: 733–43PubMedCrossRefGoogle Scholar
  43. 43.
    European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medications in the European Community Respiratory Health Survey (ECHRS). Eur Resp J 1996; 9: 687–95CrossRefGoogle Scholar
  44. 44.
    The Asthma and Respiratory Foundation. Asthma in New Zealand [online]. Available from URL: http://www.asthmanz.co.nz/in_new_zealand.php [Accessed 2007 Mar 28]
  45. 45.
    The Asthma Foundation of Victoria. Asthma: the figures [online]. Available from URL: http://www.asthma.org.au/Default.aspx?.tabid=35 [Accessed 2007 Mar 28]
  46. 46.
    Lethbridge-Cejky M, Rose D, Vickeri J. Summary health statistics for U.S. adults: National Health Interview Survey, 2004. National Center for Health Statistics. Vital Health Stat Series 10 2006; (228): 1–154Google Scholar
  47. 47.
    Bloom B, Dey AN. Summary health statistics for U.S. children: National Health Interview Survey, 2004. National Center for Health Statistics. Vital Health Stat 10 2005; (231): 1–84Google Scholar
  48. 48.
    Department of Public Health Sciences. King’s College London. European Community Respiratory Health Survey II. Final Report: May 2004 [online]. Available from URL: http://www.ecrhs.org/Progress/ecrhsIIfinalreport.pdf [Accessed 2007 Mar 28]
  49. 49.
    Cerveri I, Locatelli F, Zoia MC, et al. on behalf of the ECRHS. International variations in asthma treatment compliance. Eur Respir J 1999; 14: 288–94PubMedCrossRefGoogle Scholar
  50. 50.
    GlaxoSmithKline. The state of asthma in America: asthma in America survey. A landmark survey: executive summary [online]. Available from URL: http://www.asthmainamerica.com/aaa_index.html [Accessed 2007 Mar 28]
  51. 51.
    GlaxoSmithKline. The state of asthma in America: children and asthma in America survey. Executive Summary [online]. Available from URL: http://www.asthmainamerica.com/children_index.html [Accessed 2007 Mar 28]
  52. 52.
    Vermiere PA, Rabe KF, Soriano JB, et al. Asthma control and differences in management practices across seven European countries. Respir Med 2002; 96: 142–9CrossRefGoogle Scholar
  53. 53.
    Weiss KB, Sullivan SD. The health economics of asthma and rhinitis: I. Assessing the economic impact. J Allergy Clin Immunol 2001; 107: 3–8PubMedCrossRefGoogle Scholar
  54. 54.
    Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985–1994. J Allergy Clin Immunol 2000; 106: 493–9PubMedCrossRefGoogle Scholar
  55. 55.
    National Institutes of Health, National Heart Lung and Blood Institute. Morbidity & mortality: 2004 chart book on cardiovascular, lung, and blood diseases [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf [Accessed 2007 Mar 28]
  56. 56.
    Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111: 1212–8PubMedCrossRefGoogle Scholar
  57. 57.
    National Asthma Council. Report on the cost of asthma in Australia [online]. Available from URL: http://www.nationalasthma.org.au/html/strategy/camia/index.asp [Accessed 2007 Mar 28]
  58. 58.
    Braman SS. The global burden of asthma. Chest 2006; 130 (1 Suppl.): 4S–12SPubMedCrossRefGoogle Scholar
  59. 59.
    Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156: 787–93PubMedGoogle Scholar
  60. 60.
    Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. A large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92: 32–9PubMedCrossRefGoogle Scholar
  61. 61.
    Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61–7PubMedCrossRefGoogle Scholar
  62. 62.
    Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to degree of severity. Eur Respir J 1998; 12: 1322–6PubMedCrossRefGoogle Scholar
  63. 63.
    Holt S, Beasley R. The burden of asthma in New Zealand. Wellington (NZ): Asthma and Respiratory Foundation of New Zealand, Inc., 2002: 35Google Scholar
  64. 64.
    Akinbami LJ. Advance data from vital and health statistics. The state of childhood asthma, United States, 1980-2005 [online]. Available from URL: http://www.cdc.gov/nchs/data/ad/ad381.pdf [Accessed 2007 Mar 26]
  65. 65.
    Federico MJ, Liu AH. Overcoming childhood asthma disparities of the inner-city. Pediatr Clinics North Am 2003; 50: 655–75CrossRefGoogle Scholar
  66. 66.
    Gergen PJ. Understanding the economic burden of asthma. J Allergy Clin Immunol 2001; 107 (5 Suppl.): S445–8PubMedCrossRefGoogle Scholar
  67. 67.
    Juniper EF. Quality of life in adults and children with asthma and rhinitis. Allergy 1997; 52: 971–7PubMedCrossRefGoogle Scholar
  68. 68.
    Kenyon NJ, Jarjour NN. Severe asthma. Clin Rev Allergy Immunol 2003; 25: 131–49PubMedCrossRefGoogle Scholar
  69. 69.
    Eisner MD, Ackerson LM, Chi F, et al. Health-related quality of life and future health care utilization for asthma. Ann Allergy Asthma Immunol 2002; 89: 46–55PubMedCrossRefGoogle Scholar
  70. 70.
    Buhl R. Omalizumab (Xolair®) improves quality of life in adult patients with allergic asthma: a review. Respir Med 2003; 97: 123–9PubMedCrossRefGoogle Scholar
  71. 71.
    Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81–7PubMedCrossRefGoogle Scholar
  72. 72.
    Holgate ST, Chuchalin A, Herbert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632–8PubMedCrossRefGoogle Scholar
  73. 73.
    Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–16PubMedCrossRefGoogle Scholar
  74. 74.
    Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe allergic asthma). Allergy 2004; 59: 701–8PubMedCrossRefGoogle Scholar
  75. 75.
    Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe asthma. Eur Respir J 2002; 20: 73–8PubMedCrossRefGoogle Scholar
  76. 76.
    Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 154–9PubMedCrossRefGoogle Scholar
  77. 77.
    Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302–8PubMedCrossRefGoogle Scholar
  78. 78.
    Genentech, Inc. Omalizumab (omalizumab for subcutaneous use) [package insert]. South San Francisco (CA): Genentech, Inc., 2006Google Scholar
  79. 79.
    US Food and Drug Administration. Center for Drug Evaluation and Research. Omalizumab (marketed as Xolair) information [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/omalizumab/default.htm [Accessed 2007 Mar 17]
  80. 80.
    US Food and Drug Administration. Center for Drug Evaluation and Research. Information for healthcare professionals: omalizumab (for subcutaneous use; marketed as Xolair) [online]. Available from URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/omalizumabHCP.pdf [Accessed 2007 Mar 17]
  81. 81.
    Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20: 1088–94PubMedCrossRefGoogle Scholar
  82. 82.
    Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111: 278–84PubMedCrossRefGoogle Scholar
  83. 83.
    Niebauer K, Dewilde S, Fox-Rushby J, et al. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 2006; 96: 316–26PubMedCrossRefGoogle Scholar
  84. 84.
    Chipps B, Buhl R, Beeh K-M, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006; 22: 2201–8PubMedCrossRefGoogle Scholar
  85. 85.
    Heavey S. US seeks tough warning on Genetech asthma drug. Reuters AlertNet 2007 Feb 21 [online]. Available at: http://www.alertnet.org/printable.htm?.URL=/thenews/newsdesk/N21302619.htm [Accessed 2007 Mar 26]
  86. 86.
    The Scottish Parliament. Business bulletin no. 10/2007: Friday 19 January 2007 [online]. Available at http://www.scottish.parliament.uk/business/businessBulletin/bb-07/bb-01-19f.htm [Accessed 2007 Mar 26]
  87. 87.
    Marcus P. Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice. Chest 2006; 129: 466–74PubMedCrossRefGoogle Scholar
  88. 88.
    Robinson JC. Insurers’ strategies for managing the use and cost of biopharmaceuti-cals. Health Aff (Millwood) 2006; 25(5): 1205–17CrossRefGoogle Scholar
  89. 89.
    Statement of medical necessity for XOLAIR® (omalizumab) for subcutaneous use [online]. Available from URL: https://www.spoconline.com/spoconline/doc/xo/xol_spoc_smn.pdf [Accessed 2007 Mar 28]
  90. 90.
    Mississippi Medicaid Bulletin. New coverage criteria for Xolair® (omalizumab): provider policy manual. August 2005 [online]. Available at URL: http://www.dom.state.ms.us/Provider/Provider_Manuals/Section_56_InjectablesPhysiciansOffice.pdf [Accessed 2007 Mar 28]
  91. 91.
    Drug Topics Red Book, 2006 edition. Montvale (NJ): Thompson PDR, 2006Google Scholar
  92. 92.
    Rambasek T, Kavuru MS. Omalizumab dosing via the recommended card versus use of the published formula [letter]. J Allergy Clin Immunol 2006; 117: 708–9PubMedCrossRefGoogle Scholar
  93. 93.
    Omalizumab (Xolair): an anti-IgE antibody for asthma. Med Lett Drugs Ther 2003; 45: 67-8Google Scholar
  94. 94.
    Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004; 114: 265–9PubMedCrossRefGoogle Scholar
  95. 95.
    Marshall GD, Sorkness CA. IgE-blocking therapy for difficult-to-treat asthma: a brief review. Managed Care 2004 March; 13: 45–50PubMedGoogle Scholar
  96. 96.
    Bootman JL, Crown WH, Luskin AT. Clinical and economic effects of suboptimally controlled asthma. Managed Care Interface 2004; 17: 31–6PubMedGoogle Scholar
  97. 97.
    Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006; 22: 1765–76PubMedCrossRefGoogle Scholar
  98. 98.
    Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007; 62: 149–53PubMedCrossRefGoogle Scholar
  99. 99.
    Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709–17PubMedCrossRefGoogle Scholar
  100. 100.
    Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immu-noglobulin E antibody in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: 233–40PubMedGoogle Scholar
  101. 101.
    Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378–86PubMedCrossRefGoogle Scholar
  102. 102.
    Biotech drugs: possibly the most expensive challenge you face. Caremark TrendsRx® Quarterly 2003; (1): 4-5 [online]. Available from URL: http://www.caremark.com/portal/asset/TrendsRxQuarterlyNewsletter_8-15.pdf [Accessed 2007 Mar 28]
  103. 103.
    Goldman DP, Joyce GF, Lawless G, et al. Benefit design and specialty drug use. Health Aff (Millwood) 2006; 25: 1319–31CrossRefGoogle Scholar
  104. 104.
    Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma. Cochrane Database Syst Rev 2006; (4): CD003559Google Scholar
  105. 105.
    American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162: 2341–51Google Scholar
  106. 106.
    Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286: 2956–67PubMedCrossRefGoogle Scholar
  107. 107.
    Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253–9PubMedCrossRefGoogle Scholar
  108. 108.
    Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274–80PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.School of PharmacyMassachusetts College of Pharmacy and Health SciencesWorcesterUSA

Personalised recommendations